PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) has achieved a significant milestone with the FDA's recent approval of Cobenfy ...

PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. The Boston, Massachusetts-based biotechnology company said the milestone ...

Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the ...

The Fed had long been keeping its main interest rate at a two-decade high in hopes of slowing the economy enough to stifle ...

Christine Lagarde is under pressure to ramp up the pace of interest rate cuts in the eurozone after French and Spanish ...

Stocks in China got a boost after the central bank cut its main policy rate and financial institutions’ reserve requirement ratio in a bid to boost lending. The People’s Bank of China cut the ...

London stocks had extended gains by midday on Friday as Chinese markets enjoyed their best week since 2008 on the back of ...

Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301, with BeiGene's anti-PD-1 antibody tislelizumab, ...

(Sharecast News) - London stocks closed higher on Friday as investors digested a slowdown in the Federal Reserve's preferred inflation measure. The FTSE 100 gained 0.43% to reach 8,320.76, while the ...

Bristol-Myers Squibb (BMY) shares rose early Friday as the biopharmaceutical company obtained approval from the US Food and Drug Administration for its Cobenfy drug to treat schizophrenia in adults.

Wall Street pushed higher on Friday, following in the steps of the FTSE 100 ( ^FTSE) and European stocks as a key measure of ...

At the e4m iDAC 2024 summit, regional agency leaders explored the vital balance between traditional and digital media, while ...